Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1182 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07548697Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT1182 in B-cell non-Hodgkin lymphoma. Primary endpoints: Adverse Events at 24 months and Dose-Limiting Toxicity at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
CT1182
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07548697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548697.